Immutep Ltd has released a press release.
IMP321 demonstrates positive safety & efficacy qualities
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Approval received to commence 3rd cohort of melanoma trial
- $492k R&D Tax Incentive Refund Received
- PRR completes recruitment for 2nd patient cohort
- US patent granted for IMP321
- French Research Tax Credit Payment Received
Later from Immutep
- USD 5 Million Capital Raising
- Form 6-K
- Disclosure Under LR 3.10.5A and 7.1A.4(b)
- Approvals received to initiate INSIGHT clinical trial
- 2nd milestone payment to be received from Novartis
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep